蚕豆萎蔫病毒单克隆抗体制备及检测应用

:用蚕豆萎蔫病毒(BBWV)免疫的BALB/C鼠脾细胞与SP2/0鼠骨髓瘤细胞融合,经筛选克隆,获得6株能稳定传代并分泌抗BBWV单克隆抗体(Mab)的杂交瘤细胞株,单抗腹水ELISA滴度为1:320000～1:640000,各单抗抗体类型均为IgG1。6株单抗与BBWV不同分离物均有反应,而与其它植物病毒无交叉反应。经Westernblot印迹分析表明,此6株单克隆抗体均是针对BBWV447kD的外壳蛋白大亚基的特异性抗体。这是国内外首次报道获得BBWV单克隆抗体     

牛IFN-γ原核表达、单克隆抗体制备及其ELISA检测方法的建立

实验旨在建立牛重组IFN-γ(BovIFN-γ)的ELISA检测技术,为牛传染病的免疫学诊断提供新方法。PHA刺激体外培养的奶牛外周血白细胞,从培养细胞中提取总RNA,经过RT-PCR扩增出BovIFN-γ基因cDNA,进一步克隆至pET28a,转化大肠杆菌,经IPTG诱导,表达出预期大小(18kD左右)组氨酸标记蛋白,经鉴定为BovIFN-γ;以纯化的重组BovIFN-γ为免疫原,应用淋巴细胞杂交瘤技术,获得4株能稳定分泌抗BovIFN-γ单克隆抗体的细胞株,分别命名为A7、A10、G6与G10。免疫球蛋白亚类鉴定证明杂交瘤细胞所分泌的抗体均为IgG1,腹水效价在1∶210×100~1∶211×100之间。Western-blot分析显示,4株单抗均能特异性结合重组BovIFN-γ。ELISA试验表明,4株单抗只与融合蛋白BovIFN-γ反应,而不与非相关性蛋白Ag85B、ESAT-6-CFP-10、GM-CSF等发生反应。选取A10细胞株分泌的单克隆抗体、纯化的多克隆抗体及辣根过氧化物酶(HRP)标记的羊抗兔IgG,建立了检测BovIFN-γ的双抗体夹心ELISA方法。实验结果表明,此方法检测敏感性达到2ng/mL,特异性良好,为进一步建立灵敏、特异的病原感染诊断方法奠定了基础。     

抗羊口疮病毒ORFV118蛋白单克隆抗体的制备、鉴定及其应用

制备抗羊口疮病毒118(ORFV118)重组蛋白的单克隆抗体并鉴定其生物学特性。构建ORFV118原核表达重组质粒pET33b-ORFV118,将重组质粒转化大肠杆菌BL21,诱导表达出ORFV118重组蛋白;利用Ni-NTA亲和层析法纯化ORFV118重组蛋白;以纯化蛋白为抗原免疫小鼠,通过杂交瘤技术制备单克隆抗体;利用间接ELISA法、Western blot、免疫组化等方法分别对单抗特异性、效价、亚型以及ORFV118蛋白的功能进行研究。获得了3株稳定分泌单克隆抗体的细胞株,分别命名为1A2,3B5,5D10,它们诱生的小鼠腹水效价分别为110 000,16 400,18 000。其中效价最高的1A2抗体亚型为IgG1,能特异性结合其免疫原蛋白、真核表达产物以及病羊皮肤组织中的ORFV118蛋白。免疫组化结果显示单抗1A2染色局限于皮肤表皮层角化细胞及浸润至皮下组织的炎症细胞,与病毒侵染上皮组织层的特性相符。制备的单抗1A2能特异性识别ORFV118。深入研究单抗1A2将为了解ORFV118的生物学特性,为羊传染性脓疱病的诊断、预防与治疗提供可能和新思路。     

空肠弯曲菌FlaA单克隆抗体的制备与鉴定

【目的】原核表达空肠弯曲菌鞭毛蛋白FlaA,并制备其单克隆抗体。【方法】克隆目的基因并将其构建到pET30a(+)和pGEX-6p-1表达载体,分别以变复性纯化后的rHis-FlaA、rGST-FlaA蛋白为免疫原和检测原进行杂交瘤细胞的筛选。采用间接ELISA法测定细胞上清和单抗腹水效价,Dot-ELISA、Western blot分析单抗特异性。【结果】成功构建pET30a(+)-flaA和pGEX-6p-1-flaA重组原核表达质粒,并融合表达rHis-FlaA和rGST-FlaA蛋白,Western blot试验显示天然蛋白多抗血清能与体外表达的蛋白呈现特异性反应,表明表达蛋白具有免疫原性。筛选获得3株稳定分泌抗FlaA的单克隆杂交瘤细胞株,分别命名为2D12、5E12、6A9,其Ig亚类分别为IgG2a、IgG1、IgG1,腹水效价分别为1∶102400,1∶102400和1∶51200;Western blot试验显示,3株单抗均能与表达rHis-FlaA重组蛋白的细菌发生特异性反应;Dot-ELISA试验表明,3株单抗均能与不同来源的空肠弯曲菌分离株发生特异性反应。【结论】本研究制备的单克隆抗体有较高特异性,具有良好的应用价值。为进一步研究空肠弯曲菌鞭毛蛋白的生物学特性、致病机理,以及建立快速检测技术奠定基础。     

产单核细胞李斯特菌actA基因在大肠杆菌中的表达及其单克隆抗体的研制

利用PCR技术从血清型1/2a的产单核细胞李斯特菌Lm-4株中扩增出actA基因,经克隆筛选和测序鉴定后,构建成该基因的原核表达载体pGEX-6P-1-actA及pET-actA,转入E·coli后,IPTG诱导目的蛋白的表达。SDS-PAGE结果表明,actA基因在两种载体中均获得表达,融合蛋白的大小分别约为120kDa和97kDa。以纯化蛋白为材料进行了ActA单抗的研制,获得4株抗ActA的单克隆抗体杂交瘤细胞株,腹水单抗ELISA效价为1∶5×104~1∶1×105。选取单抗1A5进行Westernblot分析,结果表明单抗1A5能和表达产物进行特异性反应,且与Lm-4多抗血清的Westernblot结果一致。actA基因的原核表达及单抗的研制为研究ActA蛋白的生物学活性及其致病作用奠定了基础。     

HBV前S2蛋白单克隆抗体的制备和生物学特性的鉴定

目的克隆表达HBV前S2蛋白,用纯化的重组蛋白GST-S2免疫BALB/C小鼠,通过杂交瘤技术制备抗HBV前S2蛋白的单克隆抗体(mAb),并鉴定其特性.方法利用含双拷贝乙肝病毒adw2亚型基因全序列的质粒pEcob6,经PCR方法扩增出HBV前S2片段,在GST表达系统中表达,表达产物用谷胱甘肽亲和层析纯化后,用于免疫BALB/c小鼠,采用杂交瘤技术制备抗前S2蛋白的mAb,采用间接ELISA方法和Western blot进行mAb特异性鉴定;同时采用间接ELISA方法鉴定mAb相对亲和力.结果获得一株可分泌特异性mAb的杂交瘤细胞7A6;相对亲和力均在107以上.Western blot显示该株mAb能特异识别重组前S2蛋白.结论成功地制备出抗HBV前S2蛋白的一株mAb.     

汉滩病毒M、S基因不同拼接方式在昆虫细胞中融合表达效果比较

将汉滩病毒囊膜糖蛋白G1与核蛋白(NP)部分片段以不同方式拼 接,构建G1S0.7或S0.7G1嵌合基因,分别插入杆状病毒表达载体pFBD,转化DH10Bac致敏菌, 获得含有嵌合基因的重组穿梭质粒Bacmid,用其转染Sf9细胞,快速筛选出含有G1S0.7或S0.7 G1嵌合 基因的重组杆状病毒,在昆虫细胞中表达外源融合蛋白.利用间接免疫荧光、ELISA和免疫 印迹对表达产物进行检测.结果表明,含G1S0.7嵌合基因之重组杆状病毒可在昆虫细胞中表 达出融合蛋白,该蛋白可被抗汉滩病毒核蛋白及糖蛋白G1特异性单抗所识别,其分子量约97 kD;含S0.7G1嵌合基因之重组杆状病毒在昆虫细胞中表达的融合蛋白,只能被抗汉滩病毒核 蛋白特异性单抗所识别,其分子量约43kD.上述结果提示,G1S0.7嵌合基因可能在昆虫细胞 中表达出完整的具有生物学活性的融合蛋白,S0.7G1嵌和基因的昆虫细胞表达产物不完整 ,且生物学活性不如G1S0.7嵌合基因的表达产物.     

汉滩病毒M、S基因不同拼接方式在昆虫细胞中融合表达效果比较

将汉滩病毒囊膜糖蛋白G1与核蛋白 (NP)部分片段以不同方式拼接 ,构建G1S0 .7或S0 .7G1嵌合基因 ,分别插入杆状病毒表达载体 pFBD ,转化DH10Bac致敏菌 ,获得含有嵌合基因的重组穿梭质粒Bacmid ,用其转染Sf9细胞 ,快速筛选出含有G1S0 .7或S0 .7G1嵌合基因的重组杆状病毒 ,在昆虫细胞中表达外源融合蛋白。利用间接免疫荧光、ELISA和免疫印迹对表达产物进行检测。结果表明 ,含G1S0 .7嵌合基因之重组杆状病毒可在昆虫细胞中表达出融合蛋白 ,该蛋白可被抗汉滩病毒核蛋白及糖蛋白G1特异性单抗所识别 ,其分子量约 97kD ;含S0 .7G1嵌合基因之重组杆状病毒在昆虫细胞中表达的融合蛋白 ,只能被抗汉滩病毒核蛋白特异性单抗所识别 ,其分子量约 4 3kD。上述结果提示 ,G1S0 .7嵌合基因可能在昆虫细胞中表达出完整的具有生物学活性的融合蛋白 ,S0 .7G1嵌和基因的昆虫细胞表达产物不完整 ,且生物学活性不如G1S0 .7嵌合基因的表达产物     

人凝血因子Ⅶ单克隆抗体的制备与鉴定

目的：制备抗人凝血因子Ⅶ单克隆抗体并鉴定其特性。方法：应用杂交瘤融合技术,以重组人凝血因子Ⅶ为抗原免疫BALB／c小鼠;取免疫小鼠的脾细胞与Sp2／0骨髓瘤细胞融合,经间接ELISA法筛选、融合细胞有限稀释法克隆、克隆化杂交瘤细胞株的亚类鉴定等方法筛选出单克隆抗体杂交瘤细胞株,并对单克隆抗体的特异性进行鉴定;用杂交瘤细胞株诱生小鼠腹水,应用蛋白A亲和层析法进行单抗的纯化。结果：获得了3株可稳定分泌单克隆抗体的杂交瘤细胞3E8、3D2和1C5,诱生的腹水效价分别为1：1×10^7、1：1×10^6和1：1×10^6;亚类鉴定表明388为IgG2a,其余2株均为IgGl;特异性鉴定显示它们与多种血浆蛋白均无交叉反应,表明单抗是特异的;经过亲和层析,获得了纯化的单抗。结论：获得了特异性的人凝血因子Ⅶ单克隆抗体,为建立人凝血因子Ⅶ检测及纯化方法奠定了基础。     

H5亚型禽流感病毒单抗-生物素捕获ELISA的建立

目的建立一种单克隆抗体介导的、经生物素—亲和素系统放大的H5亚型禽流感病毒捕获ELISA检测方法,为进一步研究检测试剂盒提供基础。方法用亲和层析法纯化抗禽流感病毒H5亚型血凝素单克隆抗体,包被微量反应板,用于捕获病毒抗原,再用生物素标记的单抗和酶标亲和素来检测病毒血凝素抗原,经方阵试验优化ELISA反应体系。用该方法检测H1—H15亚型AIV标准毒株和H5、H7、H9亚型AIV分离株,并与血凝和血凝抑制试验比较,评价其敏感性和特异性。结果纯化后的单抗具有良好的反应活性,生物素标记单抗工作浓度为1∶5000;ELISA对H5亚型AIV的检出限为025个血凝单位。该ELISA反应体系能检出H5N3标准株和所有20株国内H5亚型AIV分离株,而与其他14个血凝素亚型的AIV标准株、15个H9亚型AIV分离株和2个H7亚型AIV分离株均无交叉反应。结论初步建立了检测H5亚型禽流感病毒的单抗—生物素捕获ELISA方法,为研制试剂盒和进一步应用试验提供了基础。     

Identification of two antigenic epitopes on SARS-CoV spike protein

The spike (S) protein of severe acute respiratory syndrome-coronavirus (SARS-CoV) is a major virion structural protein. It plays an important role in interaction with receptor and inducing neutralizing antibodies. In the study, six tentative antigenic epitopes (S1 S2 S3 S4 S5 S6) of the spike protein of SARS-CoV were predicted by bio-informatics analysis, and a multi-epitope chimeric gene of S1-S2-S3-S4-S5-S6 was synthesized and fused to downstream GST gene in pGEX-6p-1. The Western blotting demonstrated that SARS patient convalescent serum could recognize the recombinant fusion protein. A number of monoclonal antibodies were developed against the fusion protein. In further, the six predicted epitope genes were individually fused to GST of pGEX-6p-1 and expressed in Escherichia coli BL21, respectively. Among six fusion peptides, S5 reacted with monoclonal antibody D3C5 and S2 reacted with monoclonal antibody D3D1 against spike protein of SARS-CoV. The epitopes recognized by monoclonal antibodies D3C5 and D3D1 are linear, and correspond to 447-458 and 789-799 amino acids of spike protein of SARS-CoV, respectively. Identification of antigenic epitope of spike protein of SARS-CoV could provide the basis for the development of immunity-based prophylactic, therapeutic, and diagnostic techniques for the control of severe acute respiratory syndrome.     

抗传染性法氏囊病病毒VP5蛋白单克隆抗体的制备与初步应用

原核表达的IBDVGx-VP5蛋白经纯化后免疫8周龄的BALB/c雌性小鼠,三次基础免疫后,融合前加强免疫,取脾细胞在PEG(MW1500)的作用下与SP2/0小鼠骨髓瘤细胞融合,经过三次亚克隆筛选,获得稳定分泌抗VP5蛋白的杂交瘤细胞,分别命名为4B4、6D12、3E8,以三株杂交瘤细胞制备的腹水ELISA效价分别为5×104、3.5×104、3×104,特异性实验表明三株单抗能与IBDVGt株反应。以单抗介导的间接免疫荧光检测表达Gt-VP5的VeroE6细胞,可以见到特异的荧光,能做为特异性的检测VP5蛋白的工具,为今后IBDVVP5蛋白的研究打下基础。     

Mouse × pig chimeric antibodies expressed in Baculovirus retain the same properties of their parent antibodies

The development of hybridoma and recombinant DNA technologies has made it possible to use antibodies against cancer, autoimmune disorders, and infectious diseases in humans. These advances in therapy, as well as immunoprophylaxis, could also make it possible to use these technologies in agricultural species of economic importance such as pigs. Porcine reproductive and respiratory syndrome virus (PRRSV) is an arterivirus causing very important economic losses to the industry. Passive transfer of antibodies obtained by biotechnology could be used in the future to complement or replace vaccination against this and other pig pathogens. To this end, we constructed and studied the properties of chimeric mouse × pig anti‐PRRSV antibodies. We cloned the constant regions of gamma‐1 and gamma‐2 heavy chains and the lambda light chain of pig antibodies in frame with the variable regions of heavy and light chains of mouse monoclonal antibody ISU25C1, which has neutralizing activity against PRRSV. The coding regions for chimeric IgG1 and IgG2 were expressed in a baculovirus expression system. Both chimeric antibodies recognized PRRSV in ELISA as well as in a Western‐blot format and, more importantly, were able to neutralize PRRSV in the same fashion as the parent mouse monoclonal antibody ISU25C1. In addition, we show that both pig IgG1 and IgG2 antibodies could bind complement component C1q, with IgG2 being more efficient than IgG1 in binding C1q. Expressing chimeric pig antibodies with protective capabilities offers a new alternative strategy for infectious disease control in domestic pigs. © 2009 American Institute of Chemical Engineers Biotechnol. Prog., 2009     

SARS 冠状病毒 S 蛋白受体结合结构域的表达及其表位作图

严重急性呼吸综合征 (SARS) 是一种新出现的人类传染病,该病的病原是 SARS 冠状病毒 (SARS-CoV). S 蛋白是 SARS 冠状病毒的一种主要结构蛋白,它在病毒与宿主细胞受体结合以及诱导机体产生中和抗体中起重要作用 . 研究表明 S 蛋白与受体结合的核心区域为第 318 ~ 510 氨基酸残基的片段 . 首先克隆并用 pGEX-6p-1 载体融合表达了该受体结合结构域,并且通过蛋白质印迹分析表明,该受体结合结构域融合蛋白能被 SARS 康复患者血清和 S 蛋白特异的单克隆抗体所识别 . 为了对这一区域进行抗原表位作图,进一步设计了一套 23 个覆盖受体结合结构域的长 16 个氨基酸残基的部分重叠短肽,并进行了 GST 融合表达 . 用免疫动物血清和单克隆抗体 D3D1 对 23 个融合蛋白进行蛋白质印迹和 ELISA 免疫反应性分析,结果鉴定出两个抗原表位 SRBD3(F334PSVYAWERKKISNCV349) 和表位 D3D1 (K447LRPFERDI455). 其结果对进一步分析 S 蛋白结构与功能以及诊断试剂和基因工程疫苗的研究有一定意义 .     

Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design

The spike (S) glycoprotein of severe acute respiratory syndrome coronavirus (SARS-CoV) mediates the receptor interaction and immune recognition and is considered a major target for vaccine design. However, its antigenic and immunogenic properties remain to be elucidated. In this study, we immunized mice with full-length S protein (FL-S) or its extracellular domain (EC-S) expressed by recombinant baculoviruses in insect cells. We found that the immunized mice developed high titers of anti-S antibodies with potent neutralizing activities against SARS pseudoviruses constructed with the S proteins of Tor2, GD03T13, and SZ3, the representative strains of 2002 to 2003 and 2003 to 2004 human SARS-CoV and palm civet SARS-CoV, respectively. These data suggest that the recombinant baculovirus-expressed S protein vaccines possess excellent immunogenicity, thereby inducing highly potent neutralizing responses against human and animal SARS-CoV variants. The antigenic structure of the S protein was characterized by a panel of 38 monoclonal antibodies (MAbs) isolated from the immunized mice. The epitopes of most anti-S MAbs (32 of 38) were localized within the S1 domain, and those of the remaining 6 MAbs were mapped to the S2 domain. Among the anti-S1 MAbs, 17 MAbs targeted the N-terminal region (amino acids [aa] 12 to 327), 9 MAbs recognized the receptor-binding domain (RBD; aa 318 to 510), and 6 MAbs reacted with the C-terminal region of S1 domain that contains the major immunodominant site (aa 528 to 635). Strikingly, all of the RBD-specific MAbs had potent neutralizing activity, 6 of which efficiently blocked the receptor binding, confirming that the RBD contains the main neutralizing epitopes and that blockage of the receptor association is the major mechanism of SARS-CoV neutralization. Five MAbs specific for the S1 N-terminal region exhibited moderate neutralizing activity, but none of the MAbs reacting with the S2 domain and the major immunodominant site in S1 showed neutralizing activity. All of the neutralizing MAbs recognize conformational epitopes. These data provide important information for understanding the antigenicity and immunogenicity of S protein and for designing SARS vaccines. This panel of anti-S MAbs can be used as tools for studying the structure and function of the SARS-CoV S protein.     

抗SARS-CoV N蛋白单克隆抗体的特异性及其识别抗原表位的初步鉴定

为了明确抗SARS-CoVN蛋白单克隆抗体的特异性,并鉴定其识别表位,首先在E.coli中表达了人类冠状病毒229E(HCoV-229E)和OC43(HCoV-OC4)N蛋白,用Westernblotting和间接免疫荧光方法分别检测了4株抗SARS-CoVN蛋白单克隆抗体(1-1C2、1-1D6、2-8F11和2-2E5)与HCoV-OC43和HCoV-229E及其N蛋白的交叉反应情况,而后应用12种重组截短型SARS-CoVN蛋白对上述4种单克隆抗体的识别表位进行了初步定位。结果显示:(1)在4株抗N蛋白单克隆抗体中,1-1C2、1-1D6和2-2E5不与HCoV-OC43和HCoV-229E及其N蛋白发生交叉反应,为SARS-CoVN蛋白特异性抗体;(2)2-8F11、1-1D6和2-2E5针对的抗原表位位于SARS-CoVN蛋白的aa30-60,1-1C2针对的抗原表位则位于SARS-CoVN蛋白的aa170-184。这一研究为阐明SARS-CoVN蛋白的免疫学特征,建立特异性免疫诊断技术和研究其致病机制提供了必要的依据和材料。     

DNA vaccine of SARS-Cov S gene induces antibody response in mice

The spike (S) protein, a main surface antigen of SARS-coronavirus (SARS-CoV), is one of themost important antigen candidates for vaccine design. In the present study, three fragments of the truncated S protein were expressed in E. coli, and analyzed with pooled sera of convalescence phase of SARS patients. The full length S gene DNA vaccine was constructed and used to immunize BALB/c mice. The mouse serum IgG antibody against SARS-CoV was measured by ELISA with E. coli expressed truncated S protein or SARS-CoV lysate as diagnostic antigen. The results showed that all the three fragments of S protein expressed by E. coli was able to react with sera of SARS patients and the S gene DNA candidate vaccine could induce the production of specific IgG antibody against SARS-CoV efficiently in mice with seroconversion ratio of 75% after 3 times of immunization. These findings lay some foundations for further understanding the immunology of SARS-CoV and developing SARS vaccines.     

Structural characterization of human melanoma-associated antigen p97 with monoclonal antibodies

Monoclonal antibodies were used to study p97, a human melanoma-associated antigen (MAA). Four hybridomas, designated 4.1, 96.5, 118.1, and 8.2, were obtained by fusing mouse myeloma cells with spleen cells from mice immunized with human melanoma cells. Antibodies 4.1 and 8.2 were IgG1; antibodies 96.5 and 118.1 were IgG2a. Sequential immunoprecipitation (IP) and sodium-dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) showed that all 4 antibodies recognized the same 97 kilodalton (kD) protein. Binding studies with 125I-labeled antibody showed that antibodies 4.1 and 96.5 bound the same epitope, p97a. Antibodies 118.1 and 8.2 defined epitopes p97b and p97c, respectively. Six monoclonal antibodies (M17, L1, L10, R10, I12, and K5) specific for gp95, a kD melanoma cell surface glycoprotein were also tested. Sequential IP showed that these antibodies bound p97; p97 and gp95 are thus identical. Binding studies showed that antibody m17 bound epitope p971, and antibodies L1, L10, and R19 bound epitope p97c. Antibodies I12 and K5 defined 2 other epitopes, p97d and p97e, respectively. SDS-PAGE under nonreducing conditions indicated that p97 is monomeric, probably with intrachain disulfide bonds. Cell-surface labeling of sialic acid residues and neuraminidase digestion showed that p97 is a sialoglycoprotein. Digestion of p97 with papain or trypsin produced a stable 40 kD fragment, which expressed epitopes p971, p97b, and p97c, but not p97d or p97e.     

三个HIV-1广谱中和表位与HBV S抗原融合表达可诱导小鼠特异性抗体应答

为了增强HIV-1交叉中和表位的免疫原性,本研究使用PCR克隆技术将HIV-1三个具有一定广谱中和活性的线性抗原表位ELDKWA(简称2F5)、NWFDIT(简称4E10)和GPGRAFY(简称447-52D)基因分别融合到HBV S基因的3味端,构建了分别表达这三种融合基因的天坛株重组痘苗病毒疫苗RVJ1175S-2F5、RVJ1175S-4E10和RVJ1175S-447-52D,使用这三种重组痘苗病毒感染的细胞培养上清液经分离纯化制备了三种相应的蛋白亚单位疫苗PS-2F5、PS-4E10和PS-447-52D,对重组痘苗病毒和亚单位疫苗中三种融合抗原的生物学及免疫学特性进行了比较研究.PCR和测序结果表明,三种融合基因序列正确重组到痘苗病毒TK区,HBsAg的ELISA检测表明三种融合蛋白有效表达并分泌到细胞培养上清液中,SDS-PAGE凝胶电泳显示三种纯化后的融合蛋白均含分子量为23kD和27kD两种典型HBsAg条带,Western blot证明这两个条带均能与HBsAg抗体反应,并分别能与三种表位相应的HIV-1单抗2F5、4E10和447-52D反应.小鼠免疫结果显示,三种重组痘苗病毒疫苗和三种蛋白亚单位疫苗均能诱发较高水平的HBsAg抗体和相应HIV-1交叉中和表位抗体,蛋白亚单位疫苗诱生的这两类抗体均明显高于对应的重组痘苗病毒疫苗.这些结果为进一步研究三种表位抗体的中和活性和通过不同类型疫苗联合免疫进一步增强其免疫效果研究奠定了基础.